Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr 21;19(15):2307-12.
doi: 10.3748/wjg.v19.i15.2307.

Role of interleukin-6 in Barrett's esophagus pathogenesis

Affiliations
Review

Role of interleukin-6 in Barrett's esophagus pathogenesis

Katerina Dvorak et al. World J Gastroenterol. .

Abstract

Barrett's esophagus (BE) is a metaplastic lesion of the distal esophagus arising as a consequence of chronic gastroesophageal reflux disease. Multiple studies show that BE is associated with increased risk of esophageal adenocarcinoma (EAC). Epidemiological studies and animal models demonstrate that chronic inflammation triggered by repeated exposure to refluxate predisposes to the development of BE and EAC. The chronic inflammation is associated with cytokine alterations. Interleukin 6 (IL-6) is a cytokine that stimulates cell proliferation and apoptosis resistance is frequently increased in different cancers. Importantly, IL-6 and transcriptional factor signal transducer and activator of transcription 3 (STAT3) that is activated by IL-6 are also increased in BE and EAC. This review critically appraises the role of IL-6/STAT3 pathway in progression of BE to EAC from the published evidence currently available.

Keywords: Apoptosis; Barrett’s esophagus; Bile acids; Inflammation; Interleukin 6.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Interleukin 6 signaling scheme of the interleukin 6/signal transducer and activator of transcription 3 signaling pathway. IL-6: Interleukin 6; STAT3: Signal transducer and activator of transcription 3; sIL-6R: Soluble IL-6 receptor; IL-6R: IL-6 receptor; JAK: Janus kinase; MAPK: Mitogen-activated protein kinase; VEGF: Vascular endothelial growth factor; ANG: Angiopoietin.
Figure 2
Figure 2
Apoptosis and the signaling pathways activated by bile acids. EGFR: Epidermal growth factor receptor; MAPK: Mitogen-activated protein kinase; IL-6: Interleukin 6; STAT3: Signal transducer and activator of transcription 3; COX: Cyclooxygenase; LOX: Lipooxygenase; IKK: IκB kinase; ROS: Reactive oxygen species; NF-κB: Nuclear factor kappa B; PLA2: Phospholipase A2; NAPDH: Nicotinamide adenine dinucleotide phosphate; ERK: Extracellular-signal-regulated kinase; FASR: FAS receptor; TRAILR: TRAIL receptor.

Similar articles

Cited by

References

    1. Falk GW. Barrett’s esophagus. Gastroenterology. 2002;122:1569–1591. - PubMed
    1. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146. - PubMed
    1. Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, Inadomi JM. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143:567–575. - PMC - PubMed
    1. Harrison RF, Perry I, Jankowski JA. Barrett’s mucosa: remodelling by the microenvironment. J Pathol. 2000;192:1–3. - PubMed
    1. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. - PMC - PubMed

Publication types